Trial Summary
What is the purpose of this trial?Staging of kidney cancer is primarily achieved by computerized tomography (CT) scans or magnetic resonance imaging (MRI). If a patient is found to have limited metastatic disease, surgical removal or radiation therapy could be considered in order to control the majority of the disease. However, if metastases are more widespread, systemic (drug) therapy may be the preferred management option. The identification of additional metastatic sites using more sensitive imaging modalities therefore has the potential to alter management, and this remains an unmet need in the field. This study will investigate the utility of positron emission tomography (PET) imaging with PSMA (prostate specific membrane antigen). Kidney cancer of the clear cell subtype has demonstrated high expression of PSMA, making it a disease in which PSMA-targeted PET imaging could help to identify occult metastatic disease.
What safety data exists for 18F-PSMA-1007 PET/CT imaging?The available research primarily focuses on the use of 18F-PSMA-1007 PET/CT in prostate cancer, highlighting its advantages over 68Ga-PSMA-11, such as better tumor uptake and non-urinary clearance. While the studies discuss its biodistribution and potential pitfalls, specific safety data for kidney cancer is limited. However, one study indicates that 18F-PSMA-1007 PET/CT may provide valuable insights into renal cell carcinoma, suggesting its potential utility in this area.12345
Is the treatment in the trial 'PET/CT Imaging for Kidney Cancer' a promising treatment?Yes, PET/CT imaging using PSMA is promising for kidney cancer because it helps doctors see the cancer more clearly, understand its type, and plan treatment better. It can also help in checking if the cancer has spread.34789
What data supports the idea that PET/CT Imaging for Kidney Cancer is an effective treatment?The available research shows that PET/CT imaging using F-PSMA 1007 can effectively identify kidney cancer by highlighting the primary tumor and lung nodules with intense tracer concentration. This suggests it can provide important information before surgery, such as the type of tumor and its stage. Compared to other imaging methods, like F-FDG PET/CT, F-PSMA 1007 PET/CT appears to offer more detailed insights into kidney cancer, making it a potentially useful tool for doctors in planning treatment.34689
Do I have to stop taking my current medications for the trial?The trial protocol does not specify whether you need to stop taking your current medications. However, if you need urgent systemic or radiation-based cancer treatment, you may not be eligible to participate.
Eligibility Criteria
This trial is for individuals with metastatic clear cell renal cell carcinoma. It's designed to see if a new type of PET/CT scan can find hidden cancer spread better than current methods.Inclusion Criteria
I have been diagnosed with advanced kidney cancer.
Exclusion Criteria
I cannot lie flat for 30 minutes.
My cancer does not have clear cell features.
I am under 18 years old.
I am unable to understand and agree to the study's details on my own.
My liver isn't working properly.
I need urgent cancer treatment before a PSMA scan can be done.
I have had cancer treatment before, but not for skin cancer.
I have had cancer before, but not skin cancer.
Treatment Details
[18F] PSMA-1007 PET/CT imaging is being tested to improve the detection of metastases in kidney cancer, which could influence treatment decisions between surgery, radiation, or systemic therapy.
1Treatment groups
Experimental Treatment
Group I: [18F] PSMA-1007 PET/CTExperimental Treatment1 Intervention
All patients enrolled undergo a \[18F\] PSMA-1007 PET/CT
Find a clinic near you
Research locations nearbySelect from list below to view details:
London Health Sciences Centre - Victoria HospitalLondon, Canada
Loading ...
Who is running the clinical trial?
Western UniversityLead Sponsor
References
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. [2023]Label="PURPOSE" NlmCategory="OBJECTIVE">The prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great promise in the detection of prostate cancer. However, 68Ga has several shortcomings as a radiolabel including short half-life and non-ideal energies, and this has motivated consideration of 18F-labelled analogs. 18F-PSMA-1007 was selected among several 18F-PSMA-ligand candidate compounds because it demonstrated high labelling yields, outstanding tumor uptake and fast, non-urinary background clearance. Here, we describe the properties of 18F-PSMA-1007 in human volunteers and patients.
18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. [2019]Label="PURPOSE">PSMA-targeted PET in patients with prostate cancer (PCa) has a significant impact on treatment decisions. By far the most frequently used PSMA ligand is 68Ga-labelled PSMA-11. However, due to the availability of larger amounts of activity, 18F-labelled PSMA ligands are of major interest. The aim of the present study was to evaluate the biodistribution and performance of the novel 18F-labelled ligand PSMA-1007 at two different time points.
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT. [2022]Label="PURPOSE">To investigate the utility of prostate-specific membrane antigen (PSMA)-targeted [18F]DCFPyL positron emission tomography (PET)/X-ray computed tomography (CT) imaging for the detection of sites of disease in patients with metastatic non-clear cell renal cell carcinoma (RCC).
18F-PSMA 1007 in Suspected Renal Cell Carcinoma. [2021]A 60-year-old man with suspected right renal cell carcinoma underwent F-FDG PET/CT and F prostate-specific membrane antigen (PSMA) 1007 PET/CT scan. Compared with the F-FDG PET/CT scan, F-PSMA 1007 PET/CT showed intense tracer concentration in the primary tumor in the right kidney and intense tracer concentration consistently in all lung nodules. Unlike noted in previous pilot studies with Ga-PSMA, we observed that the primary renal tumor also showed intense tracer avidity with F-PSMA 1007. F-PSMA 1007 PET/CT may provide preoperative insight into possible etiology, histopathological probability of tumor type, staging information, and theranostic potentials in evaluation of suspected renal cell carcinoma.
Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. [2021]Prostate-specific membrane antigen (PSMA)-based positron-emission tomography (PET)-computed tomography (CT) has shown great promise in prostate cancer imaging. This technique has demonstrated particular utility in the staging of high-risk primary cancer and in the localisation of recurrent disease. The use of fluorine-18 PSMA-1007 is advantageous, as it is excreted via the hepatobiliary system rather than urinary and the longer half-life of fluorine-18 compared to gallium tracers, allows for PSMA imaging in centres without a gallium generator. However, imaging with this tracer is not without flaws and areas of ambiguity remain. In this article, the biodistribution, clinical indications, and pearls of 18F-PSMA-1007 PET-CT in patients with prostate cancer will be discussed, as well as the potential pitfalls in the reporting of these studies.
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. [2022]PSMA-PET is a novel imaging modality for the staging of prostate cancer (PCa). While there are several PSMA ligands available, F-18-PSMA-1007 is particularly of interest as it is not renally excreted and therefore does not impair the imaging of the pelvic area. Hence, this study aimed to investigate the F-18-PSMA-1007-PET for the primary staging of PCa and compared it to multi-parametric (mp) MRI and histopathology.
68Ga-PSMA Uptake Patterns of Clear Cell Renal Carcinoma Across Different Histopathological Subtypes. [2023]68Ga-prostate-specific membrane antigen (PSMA) PET/CT is a well-established imaging modality in patients with prostate cancer; however, PSMA expression is also reported in the tumor-associated neovasculature, including but not limited to hepatocellular carcinoma, breast cancer, and renal cell carcinoma. Herein, we present 2 patients diagnosed with different histopathological subtypes of renal cell carcinoma who underwent 68Ga-PSMA PET/CT before surgery. Both cases have different PSMA expression characteristics and are presented along with pathological findings.
PSMA PET/CT in Renal Cell Carcinoma: An Overview of Current Literature. [2022]Although the vast majority of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging occurs in the field of prostate cancer, PSMA is also highly expressed on the cell surface of the microvasculature of several other solid tumors, including renal cell carcinoma (RCC). This makes it a potentially interesting imaging target for the staging and monitoring of RCC. The objective of this review is to provide an overview of the current evidence regarding the use of PSMA PET/Computed Tomography in RCC patients.
Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study. [2023]Label="PURPOSE" NlmCategory="OBJECTIVE">Prostate-specific membrane antigen (PSMA), in addition to its utility in prostate cancer, is also an angiogenic imaging marker for hypervascular tumors like renal cell carcinoma (RCC). Our study aims to assess the potential role of 68Ga-PSMA-11 positron emission tomography (PET)/CT in metastatic RCC and compare it with contrast-enhanced computed tomography (CECT).